Published Date: 06/01/2023
Expiration Date: 06/01/2024
Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).
The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Mechanisms of Immune-related Adverse Events (irAEs) provides an insight into the host factors that increase the risk of irAEs. The course briefly explains the differences in toxicities of CTLA-4 and PD-1 immune checkpoint inhibitors. The two case studies presented in course enables the learners to assess the immune-related response of immunotherapy treatment in a patient.
View all available ACI online offerings at www.sitcancer.org/acionline.
Estimated time to complete the activity: 45 minutes
For additional information about the accreditation of this activity, please visit https://partnersed.com
Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.
Upon completion of this activity, participants should be able to:
- Explain the Mechanisms of immune related Adverse Events in brief.
- Describe the other host factors that affect the risk of immune related Adverse Events.
- Summarize the differences in PD-L1 and CTLA-4 toxicities.
- Explain the response assessment process in a patient for the immunotherapy treatment.
Faculty and Disclosure of Conflicts of Interest
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Pradnya Patil, MD, FACP
Associate Staff Oncologist
Taussig Cancer Center, Cleveland Clinic
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Conflicts of Interest:
Consultant/Advisor/Speaker: AstraZeneca, Jazz Pharmaceuticals
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.
Pharmacy Continuing Education
PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-23-151-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Instructions for Credit
During the period 06/01/2023 through 06/01/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.